Literature DB >> 9125485

Frequency of pheochromocytoma in adrenal incidentalomas and utility of the glucagon test for the diagnosis.

G P Bernini1, M S Vivaldi, G F Argenio, A Moretti, M Sgrò, A Salvetti.   

Abstract

To investigate the frequency of pheochromocytoma in patients with incidentally discovered adrenal masses (incidentalomas) and to evaluate the sensitivity, specificity and diagnostic accuracy of the Glucagon test in comparison with resting plasma catecholamines, 89 patients with adrenal incidentalomas (age range 23-80 yr; 41 males and 48 females) were studied. Fifty-seven patients were normotensive (SBP 130+/-1.8 mmHg; DBP 80+/-0.7 mmHg, mean+/-SE) and 32 had stable hypertension (SBP 155+/-3.3 mmHg, DBP 93+/-1.4 mmHg): no patient complained of typical signs or symptoms of pheochromocytoma. Resting plasma samples for noradrenaline and adrenaline determination and, at appropriate intervals, the Glucagon test (1 mg i.v.), were performed in all subjects. Diagnosis of pheochromocytoma was made on the basis of humoral evaluations and/or surgical intervention in 6 patients (6.7%), of whom 3 hypertensives and 3 normotensives. Resting plasma catecholamines revealed 5 out of 6 patients with pheochromocytoma: in 3 cases both catecholamines were above the normal range, in 1 only adrenaline was elevated and in 1 case only noradrenaline. Similarily, the glucagon test identified 5/6 pheochromocytomas: in 3 patients the response was abnormal for both catecholamines, in 1 only for adrenaline and in 1 case only for noradrenaline. The sensitivity, specificity, and diagnostic accuracy of resting plasma catecholamines and of the glucagon test were comparable: 83.3%, 96.3%, and 95.5%, respectively. In conclusion, the frequency of pheochromocytoma in adrenal incidentalomas is not negligible, and since the diagnostic accuracy of the Glucagon test is the same of that of resting plasma catecholamines, the former does not appear to offer additional advantages in the diagnosis of incidentally discovered pheochromocytomas.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9125485     DOI: 10.1007/BF03347978

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  31 in total

1.  A survey on incidental adrenal tumors in Japan.

Authors:  Y Aso; Y Homma
Journal:  J Urol       Date:  1992-06       Impact factor: 7.450

2.  Sub-clinical Cushing's syndrome in patients with adrenal gland incidentalomas. Pitfalls in diagnosis and management.

Authors:  M K McLeod; N W Thompson; M D Gross; A G Bondeson; L Bondeson
Journal:  Am Surg       Date:  1990-07       Impact factor: 0.688

3.  Hyperfunctioning and nonhyperfunctioning benign adrenal cortical lesions: characterization and comparison with MR imaging.

Authors:  E M Remer; R M Weinfeld; G M Glazer; L E Quint; I R Francis; M D Gross; F L Bookstein
Journal:  Radiology       Date:  1989-06       Impact factor: 11.105

Review 4.  Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma.

Authors:  E L Bravo
Journal:  Endocr Rev       Date:  1994-06       Impact factor: 19.871

5.  Plasma levels of norepinephrine.

Authors:  I J Kopin; R C Lake; M Ziegler
Journal:  Ann Intern Med       Date:  1978-05       Impact factor: 25.391

6.  Biochemical diagnosis of pheochromocytoma by simultaneous measurement of urinary excretion of epinephrine and norepinephrine.

Authors:  G A Smythe; G Edwards; P Graham; L Lazarus
Journal:  Clin Chem       Date:  1992-04       Impact factor: 8.327

7.  Circulating and urinary catecholamines in pheochromocytoma. Diagnostic and pathophysiologic implications.

Authors:  E L Bravo; R C Tarazi; R W Gifford; B H Stewart
Journal:  N Engl J Med       Date:  1979-09-27       Impact factor: 91.245

8.  Biochemical tests for pheochromocytoma: strategies in hypertensive patients.

Authors:  M J Young; C Dmuchowski; J W Wallis; G P Barnas; B Shapiro
Journal:  J Gen Intern Med       Date:  1989 Jul-Aug       Impact factor: 5.128

9.  Phaeochromocytoma in Queensland--1970-83.

Authors:  L Hartley; D Perry-Keene
Journal:  Aust N Z J Surg       Date:  1985-10

10.  Clinically unsuspected pheochromocytomas. Experience at Henry Ford Hospital and a review of the literature.

Authors:  N K Krane
Journal:  Arch Intern Med       Date:  1986-01
View more
  4 in total

Review 1.  Endocrine incidentalomas--challenges imposed by incidentally discovered lesions.

Authors:  Dimitra A Vassiliadi; Stylianos Tsagarakis
Journal:  Nat Rev Endocrinol       Date:  2011-06-28       Impact factor: 43.330

Review 2.  Approach to the patient with an adrenal incidentaloma.

Authors:  Lynnette K Nieman
Journal:  J Clin Endocrinol Metab       Date:  2010-09       Impact factor: 5.958

Review 3.  Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management.

Authors:  Graeme Eisenhofer; Graham Rivers; Alejandro L Rosas; Zena Quezado; William M Manger; Karel Pacak
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

4.  Low sensitivity of glucagon provocative testing for diagnosis of pheochromocytoma.

Authors:  Jacques W M Lenders; Karel Pacak; Thanh-Truc Huynh; Yehonatan Sharabi; Massimo Mannelli; Gennady Bratslavsky; David S Goldstein; Stefan R Bornstein; Graeme Eisenhofer
Journal:  J Clin Endocrinol Metab       Date:  2009-11-06       Impact factor: 5.958

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.